Welcome to our dedicated page for Medipharm Labs news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on Medipharm Labs stock.
MediPharm Labs Corp (MEDIF) is a leader in pharmaceutical-grade cannabis extraction and precision cannabinoid manufacturing, serving global medical markets through GMP-certified facilities. This page aggregates official news and verified updates about the company’s strategic initiatives, regulatory compliance milestones, and international expansion efforts.
Investors and industry professionals will find timely reports on earnings, partnership announcements, product innovations, and quality control advancements. Our curated collection simplifies tracking MEDIF’s progress in developing non-combustible delivery systems and expanding into regulated markets like Germany and Australia.
All content is sourced from company releases and accredited financial publications to ensure accuracy. Bookmark this page for streamlined access to MEDIF’s latest developments in pharmaceutical cannabis manufacturing, B2B white-label services, and API production.
MediPharm Labs Corp. announces it will release its second quarter financial results for the period ending June 30, 2022, before markets open on August 15, 2022. The executive management team will host a conference call on the same day at 8:30 a.m. ET to discuss the results and future outlook. MediPharm specializes in pharmaceutical-quality cannabis concentrates and has a Drug Establishment Licence from Health Canada, allowing it to operate under strict Good Manufacturing Practices. The call can be accessed via a toll-free number or audio webcast, with a replay available shortly after the call.
MediPharm Labs has signed a research support agreement with USC's Keck School of Medicine for a Phase 2 trial assessing THC and CBD's efficacy in treating agitation in hospice-eligible dementia patients. The study, named Life's End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY), will involve around 150 participants across 20 U.S. sites and is funded by a US$16M grant from the National Institutes of Health. MediPharm Labs will supply the study drug and placebo, reinforcing its position in the pharmaceutical cannabis sector.
MediPharm Labs Corp. (OTCQX: MEDIF) announced a favorable summary judgment in the Ontario Court of Justice, securing $9.8M related to a supply agreement dispute with a customer. This judgment will significantly enhance the company's financial position, along with a recent conditional sale of its Australian facility, adding over $16M in cash. CEO David Pidduck emphasized that this influx will strengthen their balance sheet and provide opportunities for mergers and acquisitions.
MediPharm Labs Corp. has signed a Share Purchase Agreement with OneLife Botanicals for the sale of its wholly-owned subsidiary, MediPharm Labs Australia Pty Ltd, valued at $6.9M AUD ($6.2M CAD
MediPharm Labs Corp. held its annual shareholders' meeting on June 30, 2022, with 20.564% of common shares represented. All nominees for director were elected, with Chris Halyk receiving 36,883,329 votes. KPMG LLP was appointed as auditor, receiving 52,284,746 votes in favor. An amendment to the equity incentive plan to increase the limit from 10% to 15% was approved, garnering 30,897,488 votes for and 9,540,462 against. The company continues to focus on providing quality cannabinoid products and has received a Pharmaceutical Drug Establishment Licence from Health Canada.
MediPharm Labs Corp. reported its Q1 2022 financial results, revealing a revenue decline to $4.88 million from $5.50 million in Q1 2021. Despite the drop, the company is expanding its market presence, having entered the U.S. pharmaceutical market with a completed FDA Drug Master File for CBD APIs, and has begun product deliveries to the U.K. and Brazil. The company remains debt-free and holds ownership of key assets. In March 2022, MediPharm completed the acquisition of Shelter Cannabis, enhancing its product portfolio.
MediPharm Labs Corp. (OTCQX: MEDIF) has announced it will release its fourth quarter financial results for the period ending March 31, 2022, on May 16, 2022, before market opening. An audio conference call will take place on the same day at 8:30 a.m. ET to discuss the results and company outlook. MediPharm specializes in the development of pharmaceutical-quality cannabis products and holds a unique Drug Establishment License from Health Canada, enabling compliance with Good Manufacturing Practices.
MediPharm Labs Corp. has appointed David Pidduck as its new CEO and Director, effective April 20, 2022. He replaces Bryan Howcroft, who steps down for personal reasons. Pidduck brings over 20 years of leadership experience in the pharmaceutical sector. Under his leadership, the company aims to enhance its sales pipeline and focus on revenue growth and profitability. He has been awarded stock options and RSUs contingent upon regulatory approvals. MediPharm Labs specializes in high-quality cannabis products and holds a unique Good Manufacturing License in North America.
MediPharm Labs Corp has announced the expansion of its wellness product line by introducing naturally derived cannabigerol (CBG) products and a water-soluble cannabinoid solution. The new products include a CBG:CBD 1:2 oil, named Advanced Formula, and a CBG vape cartridge called Northbound, available in Ontario. With a focus on quality and therapeutic benefits, the company aims to meet the rising demand for cannabinoid products. CEO Bryan Howcroft emphasized the potential for international market expansion, leveraging unique manufacturing licenses and distribution partnerships.
MediPharm Labs (MEDIF) reported its financial results for 2021, showing international sales more than doubling to $9.5 million, contributing 44% of total revenue of $21.7 million. Canadian provincial sales grew 18% to $7.4 million. The company launched new innovative products and expanded its market presence. However, it posted a significant net loss of $54.8 million, and gross profit was negative at $15.2 million. MediPharm maintains a solid financial position with $34 million in cash and no debt.
FAQ
What is the current stock price of Medipharm Labs (MEDIF)?
What is the market cap of Medipharm Labs (MEDIF)?
